NCT04770909Completed
Log2Lose: Incenting Weight Loss and Dietary Self-monitoring in Real-time to Improve Weight Management Among Adults With Obesity
Source: ClinicalTrials.gov · Last updated 20 May 2026
Brief summary (registry, in English)
This study involves an evaluation of whether providing small incentives weekly for dietary self-monitoring and/or weight loss improves short- and long-term weight loss. Participants can expect to be on study for 18 months.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 706 (actual)
- First submitted
- 22 Feb 2021
- Start date
- 13 May 2021
- Primary completion date
- 8 Apr 2024
- Lead sponsor
- University of Wisconsin, Madison
- Diseases
- Obesity
- NCT number
- NCT04770909
What you commit to
- Study type: Interventional
- Participants enrolled: 706
- From 13 May 2021 to the primary completion date, 8 Apr 2024
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Weight loss of at least 10 lbs in the month prior to screening
- Currently enrolled or enrolled in previous month in a clinical, research, or community program focusing on lifestyle change that could affect weight
- Current use of weight loss medication
- Residing in a nursing home or receiving home health care
- Unstable heart disease in the 6 months prior to screening
Other illness
- History of bariatric surgery or planning to have bariatric surgery in the study timeframe
- Significant dementia, drug or alcohol misuse, or unstable psychiatric illness (e.g., schizophrenia, psychosis)
- Current treatment for cancer or being treated for cancer (besides basal cell carcinoma or squamous cell) in the last 6 months
- Chronic kidney disease at stage 4 or 5
- History of ascites requiring paracentesis
- Pain, fainting or other conditions that prohibit mild/moderate exercise
Lab values
- Diuretic medication doses higher than hydrochlorothiazide 25 mg daily, furosemide 40 mg daily, torsemide 20 mg daily, bumetanide 1 mg daily, or any use of metolazone; use of potassium-sparing diuretics is acceptable
Other
- Weight \>380 lb
- Impaired hearing
- Use of insulin, sulfonylureas, or meglitinides due to increased risk for hypoglycemia
- Pregnant, breastfeeding, or planning to become pregnant within the study timeframe
- Exertional chest pain
Who the study is looking for
- BMI ≥30 kg/m2
- Desire to lose weight
- Agrees to attend outcome visits per protocol
- Available for class times
- Transportation and ability to attend in-person study visits at baseline (screening), 26, 52, and 78 weeks
- Able to stand for weight measurements without assistance
- Able to speak and read English
- Able to download and use the MyFitnessPal and Fitbit apps daily
- Possess smart phone with data and texting plan
- Have or willing to create a Gmail address
- Able to connect to a video conference call using a smartphone, tablet or computer with a webcam and microphone
- Score of at least 4 out of 6 on a validated cognitive screener
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Duke University Medical Center Coordinator of this site? Confirm its status | Durham | United States | Unknown status |
| University of Wisconsin - Madison Coordinator of this site? Confirm its status | Madison | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.